Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.99−0.01 (-0.25%)
Close on Nov 18, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
No pe ratio figures for Taysha Gene Therapies
Taysha Gene Therapies has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?